Effect of Lactoferrin in Pneumonia Treatment

NCT ID: NCT05431023

Last Updated: 2022-06-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-01
• Study Completion Date: 2024-08-01

Brief Summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children.

Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000).

Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Detailed Description

Lactoferrin (LF) is iron-binding glycoprotein of the transferrin family that is expressed and secreted by glandular cells and is found in most body fluids . It appears at especially high concentrations in mammalian milk and was first identified in bovine milk , and was subsequently isolated from human milk.

LFs bacteriostatic function is due to its ability to take up the Fe3+ ion, limiting use of this nutrient by bacteria at the infection site and inhibiting the growth of these microorganisms as well as the expression of their virulence factors .

Conditions

Pneumonia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with pneumonia who receive only treatment for pneumonia

They receive only treatment for pneumonia

Group Type: EXPERIMENTAL

Pneumonia treatment

Intervention Type: DRUG

Antibiotics for pneumonia

pneumonia patients receive treatment for pneumonia and lactoferrin

They receive treatment for pneumonia and lactoferrin

Group Type: EXPERIMENTAL

Lactoferrin

Intervention Type: DRUG

Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection

Pneumonia treatment

Intervention Type: DRUG

Antibiotics for pneumonia

Interventions

Lactoferrin

Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection

Intervention Type: DRUG

Pneumonia treatment

Antibiotics for pneumonia

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Pneumonia patients
• from the age of one month to the age of 18 years .

Exclusion Criteria

Neonates and any children with :

• immune deficiency
• congenital heart disease
• neuromascular disorder
• genetic syndromes

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Omima mahran hussein

Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

Pneumonia

Identifier Type: -

Identifier Source: org_study_id